MDXG : Summary for MiMedx Group, Inc - Yahoo Finance

U.S. Markets closed

MiMedx Group, Inc. (MDXG)


NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
8.29+0.02 (+0.24%)
At close: 4:00PM EST
People also watch
OSIRNEOMACKTGTXHALO
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close8.27
Open8.29
Bid0.00 x
Ask0.00 x
Day's Range8.18 - 8.30
52 Week Range6.64 - 10.02
Volume405,151
Avg. Volume661,190
Market Cap907.88M
Beta0.66
PE Ratio (TTM)45.80
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • PR Newswire3 days ago

    MiMedx Announces Release Date for 2016 Full Year Results

    MiMedx® is an integrated developer, processor and marketer of patent protected and proprietary regenerative biomaterial products and bioimplants processed from human amniotic membrane and other human birth tissues, such as amniotic fluid, umbilical cord and placental collagen, and human skin and bone.  "Innovations in Regenerative Biomaterials" is the framework behind our mission to give physicians products and tissues to help the body heal itself.  We process the human amniotic membrane utilizing our proprietary PURION® Process, to produce a safe and effective implant. MiMedx proprietary processing methodology employs aseptic processing techniques in addition to terminal sterilization.  MiMedx is the leading supplier of amniotic tissue, having supplied over 700,000 allografts to date for application in the Wound Care, Burn, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare.

  • PR Newswire12 days ago

    Benefits Of MiMedx dHACM Allograft Chronicled In Multiple Articles In February 2017 Supplement Edition Of Annals of Plastic Surgery

    MARIETTA, Ga., Feb. 7, 2017 /PRNewswire/ -- MiMedx Group, Inc. (MDXG), the leading regenerative medicine company utilizing human placental tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, announced today that the beneficial healing effects of MiMedx dehydrated human amnion/chorion membrane allografts in burn management are demonstrated in the February 2017 supplement edition of the peer-reviewed Annals of Plastic Surgery. The peer-reviewed Annals of Plastic Surgery, Volume 78, Supplement 1, February 2017, can be found on line at http://journals.lww.com/annalsplasticsurgery/toc/2017/02001, and the hard copy will be available on February 23, 2017.

  • PR Newswire13 days ago

    MiMedx Board of Directors Authorizes $10 Million Increase to the Company's Share Repurchase Program

    MARIETTA, Ga., Feb. 6, 2017 /PRNewswire/ -- MiMedx Group, Inc. (MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, announced today the decision of its Board of Directors to authorize an increase in the Company's Share Repurchase Program. This action by the MiMedx Board of Directors authorizes an increase of $10 million to the Company's Share Repurchase Program. This action brings the total authorized to $76 million since the Share Repurchase Program commenced in May 2014.